A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

  • Bacterial Infection
Trial Status:

Completed

This trial runs in
Countries
  • Hungary
  • Latvia
  • Poland
  • Serbia
  • United States
Trial Identifier:

NCT03174795 2016-004478-16 NP39596

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.

      Hoffmann-La Roche Sponsor
      Phase 1 Phase
      NCT03174795 , NP39596 , 2016-004478-16 Trial Identifier
      RO7079901, Meropenem Treatments
      Urinary Tract Infections Condition
      Official Title

      A Non-Randomized, Open-Label, One Treatment, One Group Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Patients With a Complicated Urinary Tract Infection

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Requiring hospitalization for IV antibacterial therapy for the treatment of presumed/confirmed cUTI (including pyelonephritis)
      • Clinical signs and/or symptoms of pyelonephritis or a cUTI
      • Urine culture taken within the 48 hours (hr) period immediately preceding the first dose of study drug contains greater than (>)1x10^5 colony forming units (CFU) per milliliter (CFU/mL) of a gram negative organism
      • Negative urine pregnancy test result confirmed by a blood test
      • Agreement to remain abstinent or use a contraceptive method
      Exclusion Criteria
      • Has a concomitant infection requiring antibacterial therapy, in addition to study drug
      • Confirmed fungal urinary tract infection
      • Moderate or severe renal impairment, or end-stage renal disease requiring renal replacement therapy or a recipient of a renal transplant
      • Documented presence of immunodeficiency, or a severely immunocompromised condition or use of systemic immunosuppressant therapy
      • Any rapidly progressing disease or immediately life-threatening illness, or other terminal illness or condition with high risk of mortality meaning that the participant is considered, in the opinion of the Investigator, unlikely to survive the study period
      • Urinary tract surgery or clinically significant urogenital trauma in the one week immediately preceding study entry
      • Urinary tract infection (UTI) symptoms potentially attributable to another process (sexually transmitted infections or prostatitis)
      • Suspected or confirmed perinephric or intra renal abscess
      • Complete obstruction of any portion of the urinary tract, or a permanent urinary diversion
      • History of epilepsy, brain lesions or other significant neurological disorders
      • Use of probenecid within the 7 days before enrollment
      • Known history of clinically significant hypersensitivity or severe allergic reaction to meropenem or any other antibiotic
      • Any other ongoing condition or disease, or clinically significant abnormalities in laboratory test results that the investigator considers would render the participant unsuitable for the study
      • Women who are pregnant, planning to become pregnant, or lactating
      • Participation in a clinical study of an investigational drug or device within one month prior to enrollment
      • Prior enrollment in this study

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now